System Data

ELI SCHUMAN

*** ********** ******, **** *

Boston, MA 02127

617-***-**** ab9m7u@r.postjobfree.com

SUMMARY

Drug Discovery and Development Scientist with over 10 years’ experience in Assay Development,

Mechanistic Enzymology, Cell Culture, Automation, and Database Processing. Quick learner of lab

technology and skilled at assimilating instrumentation to improve efficiency and productivity. Thrives in a

dynamic, collaborative setting with multiple projects. Relied on for creative solutions and rapid generation

of high quality data.

PROFESSIONAL EXPERIENCE

GLAXOSMITHKLINE (Sirtris), Cambridge, MA 2010 – 2013

Scientist I 2012 – 2013

Developed assays to improve physiological relevance of Sirt1 activation and bridge in vitro to in vivo

assays using Rapidfire / Mass Spec system.

• Developed proprietary in vitro assay simulating cellular context for investigating MOA of Sirt1 activation

and improving predictive pharmacological results. Demonstrated effect of Sirt1 activation on multiple

substrates.

• Explored detection of endogenous Sirt1 activity in lysate, confirming activation of native Sirt1 by

compounds.

• Developed assay to simultaneously measure Sirt1 deacetylation and activity of full-length protein

substrate. Improved sensitivity and allowed functional readout of full-length protein substrate.

Sr. Associate Scientist 2010 – 2012

Identified and characterized activators and inhibitors of multiple Sirtuins. Managed workflow, maintenance,

and programmed automation equipment. Designed automation solutions for numerous programs.

• Conducted regular Sirt1 medchem screening, improving compound potency and SAR understanding.

• Piloted Sirt3 activator screen that identified several classes of chemical leads, resulting in initiation of

program and formation of multidisciplinary project team.

• Executed Sirt 1, 2, and 3 inhibitor programs for selectivity, potency, and SAR of new class of potent

active site inhibitors.

• Programmed and maintained MassSpec / Rapidfire system, Agilent (V11), Tecan, Biomek, Tecan and

Molecular Devices Readers.

• Found creative solutions to automation needs

Reduced MassSpec / Rapidfire downtime and costs by establishing sample preparation

pretreatment leading to use of more difficult samples such as full-length proteins and lysates to run

on instrumentation.

Created protocols for cellular, enzymatic, crystallography assays, improving throughput and quality

for lab.

BRIGHAM AND WOMEN'S HOSPITAL, Cambridge, MA 2006 – 2010

Research Specialist, Laboratory for Drug Discovery in Neurodegeneration

Managed laboratory robotics system and compound library for facility, including generating protocols and

programs for HTS assays and developing data analysis templates for database system.

• Trained and supervised research associate, maintaining small molecule library and assay plate

production.

ELI SCHUMAN PAGE TWO

E LI . SCHUMAN @ GMAIL . COM

BRIGHAM AND WOMEN'S HOSPITAL (Continued)

Guided 10+ Postdoctoral researchers annually through array of cellular and enzymatic screens.

•

Alphascreen, Reporter Gene, TR-FRET, FP.

Evaluated screening results and prioritized compounds for lead optimization. Identified novel

•

compound classes for variety of targets for development and SAR.

Planned and implemented process, delivering >150,000 compound libraries for 10+ annual projects.

•

Critical adjustment and planning as the number of screens tripled with new grant.

Built templates, loaded, and analyzed screening data (Activity Base; IDBS software suite).

•

HARVARD MEDICAL SCHOOL, Cambridge, MA 2005 – 2006

Senior Research Associate, Cancer Drug Discovery (1 year of funding)

Miniaturized and optimized cellular and enzymatic assays for HTS of cancer targets. Screened small

molecule libraries and characterized hit compounds.

• Assembled and operated automated liquid, handling system and screened >150,000 compounds with

2 targets.

• Conducted data analysis, identifying potential leads, and prioritized compounds to focus medicinal

chemistry efforts.

ABBOTT LABORATORIES, Worcester, MA 2002 – 2005

Research Associate, Assay Lab

Performed assays and characterized potency and selectivity of lead compounds.

• Generated quality potency and selectivity data for SAR with automated kinase assays. Data was

loaded and analyzed with MDL database.

• Ran ELISA assays and HPLC for detection of cytokine activity.

• Converted automated assay from 96 to 384 well plates, doubling throughput and reducing time.

ADDITIONAL RELATED EXPERIENCE

PFIZER INCORPORATED, Cambridge, MA

Automation Technician, Materials Management

EDUCATION

BS, Physiology and Neurobiology, University of Connecticut, Storrs, CT

• Lab assistant: prepared primary myocardial cells from mice colonies for electrophysiological study

• Mathematics tutor

Internship, Central Nervous System Department, Pfizer Incorporated, Groton, CT

• Recombinant DNA work

• Immunohistochemistry of knockout mice and analyze for causes of Alzheimer’s Disease

ELI SCHUMAN

1302 Commonwealth Avenue, Apt 10

Allston, MA 02134

617-***-**** ab9m7u@r.postjobfree.com

PUBLICATIONS

Jeremy S. Disch, Ghotas Evindar, Cynthia H. Chiu, Charles A. Blum, Han Dai, Lei Jin, Eli Schuman,

•

Kenneth E. Lind, Svetlana L. Belyanskaya, Jianghe Deng, Frank Coppo, Leah Aquilani, Todd L.

Graybill, John W. Cuozzo, Siva Lavu, George P. Vlasuk, Cheney Mao, and Robert B. Perni. “Discovery

of Thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2 and SIRT3.” Journal

of Medicinal Chemistry

Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW,

•

Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer

SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk

GP, Sinclair DA. “Evidence for a common mechanism of SIRT1 regulation by allosteric activators.”

Science. 2013 Mar 8;339(6124):1216 – 9

Tang X, Seyb KI, Huang M, Schuman ER, Shi P, Zhu H, Glicksman MA. “A high-throughput screening

•

method for small-molecule inhibitors of the aberrant mutant SOD1 and dynein complex interaction.” J

Biomol Screen. 2012 Mar;17(3):314 – 26

King GD, Chen C, Huang MM, Zeldich E, Brazee PL, Schuman ER, Robin M, Cuny GD, Glicksman

•

MA, Abraham CR. “Identification of novel small molecules that elevate Klotho expression.” Biochem J.

2012 Jan 1;441(1):453 – 61

Liu M, Poulose S, Schuman E, Zaitsev AD, Dobson B, Auerbach K, Seyb K, Cuny GD, Glicksman MA,

•

Stein RL, Yue Z. “Development of a mechanism-based high-throughput screen assay for leucine-rich

repeat kinase 2-discovery of LRRK2 inhibitors.” Anal Biochem. 2010 Sep 15;404(2):186 – 92

Kuohung W, Burnett M, Mukhtyar D, Schuman E, Ni J, Crowley WF, Glicksman MA, Kaiser UB. “A

•

high-throughput small-molecule ligand screen targeted to agonists and antagonists of the G-protein-

coupled receptor GPR54.” J Biomol Screen. 2010 Jun;15(5):508 – 17

Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.

•

“Identification of small molecule inhibitors of pyruvate kinase M2.” Biochem Pharmacol. 2010 Apr

15;79(8):1118 – 24

Contact this candidate